Bayer

17.09.2025 • News • Pharma

Strategic Response to a Shifting Pharma Landscape

In a time marked by global uncertainty—from shifting trade policies to evolving healthcare demands—the pharmaceutical industry faces mounting pressure to deliver both innovation and resilience. Bayer’s Pharmaceutical Division, under the leadership of Stefan Oelrich, has embarked on a strategic transformation aimed at reinforcing stability while advancing its long-term vision. In this interview, Christene Smith from CHEManager discusses with him how Bayer is navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

13.08.2025 • News

Bayer and Kumquat Biosciences agree on global collaboration

Bayer and Kumquat Biosciences announced today that they have entered into an exclusive worldwide license and collaboration to develop and commercialize Kumquat's KRAS-G12D inhibitor.

17.07.2025 • News

Bayer Extends CEO’s Term Through 2029

Bayer's Supervisory Board has unanimously decided to extend the contract with the company's CEO, Bill Anderson, until March 31, 2029.

20.03.2024 • News • Chemistry

AI-Powered Knowledge Transfer in Manufacturing

Artificial intelligence (AI) can help companies in the process industry capture, retain and access valuable historical expertise and ease the transition for new colleagues in the plant.

19.12.2023 • News

Iktos and Bayer Cooperate on Use of AI to Design Crop Protection Products

Iktos, a French company specialized in artificial intelligence (AI) for new drug design, and Bayer’s Crop Science division announced a collaboration to expand the use of AI in the discovery and development of new sustainable crop protection products.

23.10.2023 • News

Fluor Completes Bayer’s First Global Cell Therapy Launch Facility

Fluor Corporation announced today that it has completed construction of Bayer’s first global Cell Therapy Launch Facility in Berkeley, California. Completion was celebrated on October 10, 2023, at the new facility with local officials, dignitaries, Bayer employees, and clients.

10.10.2023 • News

Bayer Opens New Cell Therapy Production Facility in the US

Bayer has opened a new cell therapy production plant in Berkeley, California, USA, for the production of of BlueRock Therapeutics’ bemdaneprocel (BRT-DA01), an investigational cell therapy currently in evaluation for treating Parkinson’s disease. BlueRock Therapeutics is a clinical-stage cell therapy company and a wholly owned, independently managed subsidiary of Bayer.

30.08.2023 • News

Bayer to Build New R&D Facility at German Site in Monheim

Bayer’ Crop Science division plans to invest €220 million in a new research and development (R&D) facility at its Monheim, Germany site. This is the company’s largest single investment in its crop protection business in Germany since the founding of the Monheim campus in 1979, Bayer said.

25.07.2023 • News

Bayer Lowers its Targets for the Year 2023

Bayer adjusted its full-year outlook for 2023 downward, mainly due to a significant further decline in sales of glyphosate-based products. The group has thus joined the ranks of chemical companies that have cut their annual targets in recent days and weeks.

22.06.2023 • News

Lanxess Warns on Earnings as Buyout Talk Circles Covestro

Two former spinoffs from Bayer were competing for headlines on Jun. 19 and 20, as specialty chemicals company Lanxess issued a profit warning amid rumors that Middle East chemicals and energy behemoth Abu Dhabi National Oil Company (ADNOC) had made a takeover offer for engineering plastics producer Covestro.

16.05.2023 • News

Bayer and Bicycle in Cancer Collaboration

Bayer and UK biotech Bicycle Therapeutics have agreed to collaborate to develop and commercialize the latter’s radioconjugates for multiple oncology targets.

24.04.2023 • News

Another Turbulent AGM for Bayer?

Bayer has seen its share of turbulent shareholder meetings, and the event on Apr. 28 is likely to continue in that vein, though it would be tough to top 2019. In that year, when anger over lawsuits involving Monsanto’s Roundup herbicide boiled over, 55% voted not to discharge CEO Werner Baumann and the managing board of their responsibilities.

14.04.2023 • News

US Merck Fails to Transfer all Talc Liability to Bayer

A move by US drugmaker Merck & Co. to have Bayer assume all liability for lawsuits alleging that the talc-based Dr. Scholl's foot powder causes cancer has failed, at least in the first instance.

27.03.2023 • News

Bayer Plans to Scale Back Women’s Health R&D

Ahead of a change in leadership at the top after the upcoming annual general meeting, in interviews with news agencies Bayer is dropping hints in dribbles about future plans for its healthcare business.

16.03.2023 • News

Bayer to Spend $1 Billion on US Drug R&D

Bayer is looking to spend $1 billion on drug research and development in the United States during 2023 as part of a plan to double its sales in the country by the end of the decade.

01.03.2023 • News

Baumann Calls US Legal System Unjust

At his last – virtual – annual results press conference before handing over the CEO’s job to Bill Anderson in May, in addition to reviewing figures for 2022 and trying to assess the still clouded look for 2023, outgoing Bayer chief Werner Baumann took the opportunity to criticize the US legal system.

10.02.2023 • News

Bill Anderson to Be Bayer CEO from June 1

Bowing to growing pressure from activist investors with different missions, the supervisory board of tradition-steeped German pharmaceuticals and agrochemicals player Bayer has announced the appointment of a new CEO to succeed embattled incumbent Werner Baumann — a year before the end of the current chief executive’s regular term.

18.01.2023 • News

Bayer Shifting Pharma Focus away from Europe

Bayer is increasingly shifting the commercial focus of its pharmaceutical business away from Europe and toward the US and China, Stefan Oelrich, head of the German group’s pharmaceuticals arm, said in an interview with Financial Times during the JPMorgan Healthcare conference in San Francisco.

13.01.2023 • News

Bayer Draws Attention from Activist Investors

As Bayer’s board prepares to search for a new CEO to succeed Werner Baumann, the German pharmaceuticals and agrochemicals group has attracted the attention of two activist investors interested in pulling its share price out of the doldrums and reaping the rewards.

14.12.2022 • News

French Farmer Wins €11,000 in Bayer Herbicide Lawsuit

A French farmer who said he suffered neurological problems including memory loss, fainting and headaches after inhaling fumes from Bayer’s Lasso-branded herbicide in an agricultural accident, has won compensation of €11,135, ending more than 15 years of litigation.

16.09.2022 • News

Bayer CEO Baumann Headed for early Exit?

CEO Werner Baumann may be headed for an early exit from Bayer, Bloomberg reports.

29.08.2022 • News

Ineos Phenol to Buy Mitsui Phenols Singapore

Ineos Phenol is paying $330 million to acquire Mitsui Phenols Singapore. With the deal, expected to close in the first quarter of 2023, subject to regulatory approval, it will add 1 million tonnes of annual capacity to its production volume. The business had sales of $750 million in 2021 and 120 employees, all of whom will transfer to the new owner.

23.08.2022 • News

Bayer Rolls out US Digital Farming Platform

Under the name ForGround, Bayer is rolling out a US digital farming platform designed to help US growers use environmentally friendly practices and connect them with companies seeking more sustainable food, feed and biofuel ingredients.

19.08.2022 • News

Bayer Hires US Lobby Firm on Drug Issues

Germany’s Bayer has hired US lobby firm Williams & Jensen to aid its campaign for continued access to contraceptives.

23.06.2022 • News

US Supreme Court Won’t Hear Bayer’s Roundup Petition

After months of anticipation, the US Supreme Court has deflated Bayer’s hopes that the court’s conservative majority would vote to hear its appeal to overturn a $25 million appeals court verdict in favor of Edwin Hardeman.

21.06.2022 • News

Bayer Wins Fourth Roundup Appeal as EPA Zooms in

Bayer has won its fourth consecutive appeal of a US court case previously decided in favor of a plaintiff who claimed that Monsanto’s glyphosate-based Roundup herbicide caused his non-Hodgkin lymphoma.

15.06.2022 • News

Supreme Court Quiet on Bayer’s Roundup Petition

Despite the expectations of many, given the broad coverage in media of all types – and the case’s mention on the docket for Jun. 13 – the US Supreme Court has remained silent on whether or not it will hear Bayer’s petition on packaging labels for Monsanto’s glyphosate-based Roundup herbicide.

23.05.2022 • News

Bayer Ends CAR-T License Agreement with Atara

Bayer is stepping away from the $670 million CAR-T worldwide license agreement it entered with Atara Biotherapeutics in 2020.

12.05.2022 • News

Supreme Court Unlikely to Hear Bayer’s Roundup Plea

Bayer’s advice to shareholders expressing concern about the development of the company’s stock at its early May annual general meeting, to bide their time and wait for the US Supreme Court to deal with the issue of warning labels for agrochemicals packaging, seems to have been too hasty.

02.05.2022 • News

Bayer AGM Sees Discussion on Multiple Fronts

Like those of other chemical industry players, shareholders attending Bayer’s virtual annual general meeting on Apr. 29 had a full agenda to deal with, though their list was undoubtedly one of the longest. Along with the Russian invasion of Ukraine, they discussed potential plans to split pharma and crop science, the timetable for finally ending Roundup litigation and the size of executives’ bonuses.

20.04.2022 • News

Bayer Executives Secure Investor AGM Support

Bayer CEO Werner Baumann will receive some needed support from two major shareholder groups at the upcoming annual general meeting (AGM) but he is not out of the woods yet.

11.04.2022 • News

Bayer Sidesteps St. Louis Roundup Trial

Bayer has settled a collection of claims from US plaintiffs that Monsanto’s Roundup herbicide caused their cancer, the US newspaper St. Louis Dispatch reports. This, it said, avoids a publicity-sensitive trial that was due to start this week in the Missouri city that was Monsanto’s global headquarters before it was acquired by the German group for $63 billion in 2018.

30.03.2022 • News

Baumann Faces Fresh Challenge at Bayer AGM

Bayer CEO Werner Baumann will face a fresh leadership challenge at the company’s annual general meeting scheduled for Apr. 29. Singapore-based Temasek Holdings, which is said to have helped the German group stem its $63 billion purchase of Monsanto in 2018, has soured on the costly and still controversial acquisition and sees Baumann as having bungled it.

10.03.2022 • News

Cinven Purported Buyer of Bayer’s ESP Unit

Private equity investor Cinven is poised to acquire Bayer’s Environmental Science Professional (ESP) unit, Bloomberg has reported. The news agency’s sources said the buyer of the business put up for sale a year ago was expected to be announced in the early part of March this year.

15.02.2022 • News

Bayer Glyphosate FM Rattles Agrochemical Markets

The agrochemicals market has seen intermittent supply shortages for key herbicide ingredients for several months, and a herbicide shortfall had been predicted for the current crop growing season. With glitches following glitches, reports of a worsening market accelerated at the end of last week, when Bayer CropScience declared force majeure for glyphosate and glyphosate-based products.

595 more articles

Top-Feature

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

CHEManager International c/o Wiley-VCH GmbH

Digitalization in the Chemical Industry

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.